Aurion Biotech, a commercial-stage biotech developing regenerative cell therapies for eye diseases, withdrew its plans for an initial public offering on Friday. It originally filed in January 2025 with a proposed deal size of $100 million. Its top shareholder, ...read more
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially. ...read more
Updated Monday, 2/24. While the calendar looks quiet for the week ahead, some small deals may join late. Singapore healthcare practice Basel Medical (BMGL) is tentatively scheduled to raise $10 million at an $83 million market cap. Through its two...read more
Vision loss biotech Aurion Biotech withdraws $100 million IPO after Alcon buys a majority stake
Aurion Biotech, a commercial-stage biotech developing regenerative cell therapies for eye diseases, withdrew its plans for an initial public offering on Friday. It originally filed in January 2025 with a proposed deal size of $100 million. Its top shareholder, ...read more
US IPO Week Ahead: Small IPOs may list amid market volatility
...read more
Biotech bust: 2024 biotech IPOs average a -52% return
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially. ...read more
US IPO Week Ahead: IPO market set to end February on a quiet note
Updated Monday, 2/24. While the calendar looks quiet for the week ahead, some small deals may join late. Singapore healthcare practice Basel Medical (BMGL) is tentatively scheduled to raise $10 million at an $83 million market cap. Through its two...read more